Sign inCreate account

Report workspace tools

NCT07086755RECRUITINGanonymous

Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury

Sponsor

Source record

Bentley J. Bobrow

Phase

Source record

Phase 2/3

Modality

AI-normalized

small molecule

Target

AI-normalized

Nonintubated Acute Respiratory Distress Syndrome (ARDS) due to pathogen-associated lung injury

Indication / condition

AI-normalized

Nonintubated Acute Respiratory Distress Syndrome (ARDS)

Intervention

Source record

Vadadustat 900mg, Vadadustat 1200mg, Placebo

Source & freshness

Source record

NCT ID

NCT07086755

Original source

ClinicalTrials.gov

Source last updated

Dec 17, 2025

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07086755

Title

Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury

Sponsor

Bentley J. Bobrow

Status

RECRUITING

Phase

Phase 2/3

Condition raw

Nonintubated Acute Respiratory Distress Syndrome (ARDS)

Condition normalized

Nonintubated Acute Respiratory Distress Syndrome (ARDS)

Modality raw

Nonintubated Acute Respiratory Distress Syndrome (ARDS)

Modality normalized

small molecule

Target raw

Nonintubated Acute Respiratory Distress Syndrome (ARDS) due to pathogen-associated lung injury

Target normalized

Nonintubated Acute Respiratory Distress Syndrome (ARDS) due to pathogen-associated lung injury

Interventions

Vadadustat 900mg, Vadadustat 1200mg, Placebo

Public preview

Source record

This clinical trial evaluates the efficacy and safety of vadadustat in treating hospitalized patients with nonintubated ARDS. The study is sponsored by The University of Texas Health Science Center, Houston, in collaboration with Akebia Therapeutics. It aims to enroll approximately 1,100 participants and is currently recruiting.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07086755

Status

RECRUITING

Phase

Phase 2/3

Sponsor

Bentley J. Bobrow

Executive brief

Investment-Ready Snapshot

This clinical trial evaluates the efficacy and safety of vadadustat in treating hospitalized patients with nonintubated ARDS. The study is sponsored by The University of Texas Health Science Center, Houston, in collaboration with Akebia Therapeutics. It aims to enroll approximately 1,100 participants and is currently recruiting.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedDec 17, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07086755

Indication

Nonintubated Acute Respiratory Distress Syndrome (ARDS)

Modality

small molecule

Target

Nonintubated Acute Respiratory Distress Syndrome (ARDS) due to pathogen-associated lung injury

Intervention

Vadadustat 900mg, Vadadustat 1200mg, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.